Goldman Sachs’s Unicycive Therapeutics UNCY Stock Holding History
Bought
Maintained
Sold
Other funds holding UNCY
Goldman Sachs's UNCY Position: Q3 2026 in Review
Goldman Sachs increased its Unicycive Therapeutics (UNCY) stake by 81% in Q3 2026, buying an estimated $609K and bringing the position to 262,767 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #5076.
Goldman Sachs first reported a position in UNCY in Q2 2023 and has held it in 12 quarters since. 95 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.
- Goldman Sachs held 262,767 shares of Unicycive Therapeutics worth $1.23M as of Q3 2026.
- Goldman Sachs bought 117,463 Unicycive Therapeutics shares in Q3 2026, an estimated $609K.
- Unicycive Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #5076 holding.
- Goldman Sachs first reported a position in Unicycive Therapeutics in Q2 2023 and has held it in 12 quarters since.
- 95 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.